Search

Displaying results 3901 - 3910 of 8196 in total
  1. Drug

    Crotalus atrox antivenin

    go.drugbank.com/drugs/DB13892
    Approved

    Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species. The majority of people bitten are males and about 50% occur in the age...

  2. Drug

    Ethionamide

    go.drugbank.com/drugs/DB00609
    ApprovedInvestigationalWithdrawn

    A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)

  3. Drug

    Clofibrate

    go.drugbank.com/drugs/DB00636
    ApprovedWithdrawn

    A fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)

    Synonyms: Ethyl 2-(p-chlorophenoxy)isobutyrate, alpha-p-Chlorophenoxyisobutyryl ethyl esterCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  4. Drug

    Mexiletine

    go.drugbank.com/drugs/DB00379
    ApprovedInvestigational

    Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  5. Drug

    D-Tryptophan

    go.drugbank.com/drugs/DB03225
    Experimental

    The D-stereoisomer is occasionally found in naturally produced peptides (for example, the marine venom peptide contryphan). … The distinguishing structural characteristic of tryptophan is that it contains an indole functional group. It is an essential amino acid as defined by its growth effects on rats.

  6. Drug

    Cefovecin

    go.drugbank.com/drugs/DB11505
    ExperimentalVet approved

    However, these injectable agents can present long-lasting subtherapeutic concentrations after the resolution of infection. … The advantage of using injectable antibiotics is not missing a dose that can allow partially resistant microbes to recover during missed doses.

  7. Drug

    Satricabtagene autoleucel

    go.drugbank.com/drugs/DB18288
    Investigational

    Satricabtagene autoleucel is an autologous CAR T-cell product candidate against protein Claudin18.2 (CLDN18.2).

  8. Drug

    7MW3711

    go.drugbank.com/drugs/DB19298
    Investigational

    Developed by Mabwell, 7MW3711 is an antibody-drug conjugate targeting B7-H3.[L50918,L50923]

  9. Drug

    Teclozan

    go.drugbank.com/drugs/DB13205
    Investigational

    Teclozan is an antiprotozoal agent employed typically as a therapy to treat protozoan infections.

  10. Drug

    CT103A

    go.drugbank.com/drugs/DB18180
    Investigational

    CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.